Traws Pharma Inc. shares rose significantly by 25.98% as the stock crossed above its 5-day SMA, indicating strong buying interest despite broader market weakness.
The surge in Traws Pharma's stock price comes amid no specific news or announcements, suggesting a potential sector rotation as investors seek opportunities in biotech amidst the overall decline in the Nasdaq-100 and S&P 500 indices. This movement may reflect a shift in investor sentiment towards companies in the pharmaceutical sector, which are perceived as having growth potential even in a bearish market.
This price action could indicate a growing confidence in Traws Pharma's future prospects, potentially attracting more investors looking for stocks that can outperform the market during downturns.
Wall Street analysts forecast TRAW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRAW is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast TRAW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRAW is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.460
Low
8.00
Averages
8.00
High
8.00
Current: 2.460
Low
8.00
Averages
8.00
High
8.00
H.C. Wainwright
Brandon Folkes
initiated
$8
2025-12-03
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$8
AI Analysis
2025-12-03
initiated
Reason
H.C. Wainwright analyst Brandon Folkes initiated coverage of Traws Pharma with a Buy rating and $8 price target. The company's pipeline is led by two oral antivirals, ratutrelvir in development for COVID-19, and tivoxavir marboxil for seasonal and avian influenza, the analyst tells investors in a research note. The firm believes Traws has the potential to unlock value for shareholders if the company is able to replicate the strong early stage data.
About TRAW
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
